Literature DB >> 15180482

Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits.

B Dean1, E Scarr.   

Abstract

One of the conundrums of neuropharmacology is to understand the therapeutic mechanisms of action of antipsychotic drugs. Every drug with antipsychotic activity is a dopamine (DA) D(2)-like receptor antagonist and therefore this function is critical to reducing psychotic symptoms. However, the actions of the archetypal atypical antipsychotic drug clozapine go beyond antipsychotic effects because the drug is efficacious in treating psychotic symptoms that do not respond to drugs mainly directed at antagonizing the DA D(2) receptor, has benefits in cognition and has recently been shown to reduce levels of suicide. A growing understanding of the mechanisms of clozapine and other atypical antipsychotic drugs suggests that both partial and inverse agonism, as well as receptor antagonism, at specific neurotransmitter receptors is required to give full therapeutic benefits. It is, therefore, timely to review the evolving nature of the mechanisms of action of different antipsychotic drugs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15180482     DOI: 10.2174/1568007043337373

Source DB:  PubMed          Journal:  Curr Drug Targets CNS Neurol Disord        ISSN: 1568-007X


  6 in total

Review 1.  Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.

Authors:  Jiri Horacek; Vera Bubenikova-Valesova; Milan Kopecek; Tomas Palenicek; Colleen Dockery; Pavel Mohr; Cyril Höschl
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 2.  Molecular profiling of antipsychotic drug function: convergent mechanisms in the pathology and treatment of psychiatric disorders.

Authors:  Elizabeth A Thomas
Journal:  Mol Neurobiol       Date:  2006-10       Impact factor: 5.590

3.  Action potentials and amphetamine release antipsychotic drug from dopamine neuron synaptic VMAT vesicles.

Authors:  Kristal R Tucker; Ethan R Block; Edwin S Levitan
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-27       Impact factor: 11.205

4.  Treatment of Levodopa-induced Dyskinesia.

Authors:  Jayaraman Rao
Journal:  Curr Treat Options Neurol       Date:  2007-05       Impact factor: 3.598

5.  The impact of medical insurance policies on the hospitalization services utilization of people with schizophrenia: A case study in Changsha, China.

Authors:  Yi Feng; Xianjun Xiong; Qiuji Xue; Lan Yao; Fei Luo; Li Xiang
Journal:  Pak J Med Sci       Date:  2013-05       Impact factor: 1.088

6.  Dopamine activates NF-κB and primes the NLRP3 inflammasome in primary human macrophages.

Authors:  R A Nolan; K L Reeb; Y Rong; S M Matt; H S Johnson; K Runner; P J Gaskill
Journal:  Brain Behav Immun Health       Date:  2019-12-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.